

Treatment Naïve and Treatment Experienced

# Sofosbuvir + Peginterferon + Ribavirin in Genotypes 2 or 3 BOSON Trial

Foster GR, et al. 50<sup>th</sup> EASL. 2015. Abstract L05

# Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

## BOSON Trial: Study Features


### BOSON Trial: Features

- **Design:** Randomized, multicenter, open-label trial using sofosbuvir and ribavirin with or without peginterferon for treatment naive or experienced patients with chronic HCV genotype 2 or 3
- **Setting:** International at 80 sites
- **Entry Criteria**
  - Chronic HCV Genotype 2, treatment experienced, with cirrhosis
  - Chronic HCV Genotype 3, +/- treatment experienced, +/- cirrhosis
  - Platelet  $\geq 60,000$  cells/mm<sup>3</sup>
- **End-Points:** SVR12; safety

# Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

## BOSON: Treatment Arms

Week 0 12 16 24 28 36



### Drug Dosing

Sofosbuvir 400 mg once daily


Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg

Peginterferon alfa-2a: 180 ug/week

# Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

## BOSON: Results


### SVR12 by Regimen and Genotype



# Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

## BOSON: Results


### Genotype 3: SVR12 by Regimen



# Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

## BOSON: Results


### Genotype 3: SVR12 by Regimen and Cirrhosis Status



# Sofosbuvir + Ribavirin +/- Peginterferon for HCV GT 2 or 3

## BOSON: Results

### Genotype 3: SVR12 by Regimen and Treatment History



This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.